Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF^V600E Mutated Papillary Thyroid Cancer: Two Case Reports.

ABSTRACT:

Background

A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective.

Patients

Two consecutive patients with symptomatic, metastatic radioactive iodine-resistant BRAF^V600E mutated papillary thyroid cancer and poor performance status were treated initially with dabrafenib 150 mg twice daily plus trametinib 2 mg once daily, first in continuous daily dosing, then in a five-week-on and three-week-off schedule.

Results

Both patients showed rapid clinical im

SUBMITTER: White PS 

PROVIDER: S-EPMC6874808 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature